Novartis AG (LSE:0HKE)
£ 3657.04 0 (0%) Market Cap: 60.95 Bil Enterprise Value: 74.78 Bil PE Ratio: 14.34 PB Ratio: 5.34 GF Score: 77/100

Novartis AG at JPMorgan Healthcare Conference Transcript

Jan 13, 2020 / 04:00PM GMT
Richard Vosser
JP Morgan Chase & Co, Research Division - Senior Analyst

Thanks. Welcome to the 38th Healthcare Conference at JPMorgan. I'm Richard Vosser, European Pharma Analyst at JPMorgan. It's my pleasure to introduce Vas Narasimhan, CEO of Novartis, and welcome him to the conference.

Before I hand over to Vas, I'd just point out that the breakout session is in the Borgia Room after this presentation. Vas, welcome.

Vasant Narasimhan
Novartis AG - CEO

Thank you, Richard, and it's great to be here, great to open the year, as always, at JPMorgan. I'd like to give some perspectives on the journey Novartis has been on over the last couple of years. I'm now entering my third year as CEO, and I think we're making progress on the strategy we set out to become the leading medicines company powered by advanced therapy platforms and data science. Now when you think about what we set out, we set out to focus the company and focus the company around our core of Innovative Medicines while looking to accelerate certain geographies where we thought we could

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot